# A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia

> **NCT06714461** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 3500 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis

## Interventions

- **DRUG:** Leflunomide

## Key facts

- **NCT ID:** NCT06714461
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 3500 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06714461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06714461, "A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06714461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*